Core Insights - Recent data shows a nearly 130 percentage point performance gap between different products managed by the same fund manager at Morgan Stanley Fund, highlighting potential risks in the "star manager, light product" investment model [2][6] - The case raises questions about the research and investment system, risk control mechanisms, and product layout rationality within fund companies [2] Group 1: Fund Manager Performance - Lei Zhiyong, a fund manager at Morgan Stanley, achieved the best market performance in 2024 with his fund focused on the digital economy, boasting a cumulative return of 125.88% since March 2, 2023, significantly outperforming the average of 12.47% [4] - Lei manages a total of 8 funds, with some showing outstanding performance, while others, like the Morgan Stanley Innovation Mixed A fund, have underperformed, with a return of -7.72% since May 7, 2020, compared to the average of 45.38% [5][6] Group 2: Performance Disparity Among Products - Wang Dapeng, another core fund manager at Morgan Stanley, has a stark performance disparity among his products, with the best-performing fund, Morgan Stanley Health Industry Mixed A, returning 81.40%, while the worst, Morgan Stanley Health Industry Mixed C, has a return of -47.78% [6][7] - The significant performance gap raises concerns about investor trust and reflects potential deficiencies in compliance and responsibility awareness among fund managers [7] Group 3: Market and Strategy Impact - Analysts suggest that the performance of fund managers is closely linked to the alignment of their investment strategies with market conditions, indicating that external factors such as macroeconomic changes can heavily influence fund performance [8] - The phenomenon of performance disparity may also stem from fund managers' divided attention when managing multiple products, leading to varied execution priorities and outcomes [8]

Group 1 - Morgan Stanley Fund Management (China) has experienced performance divergence among its fund managers this year, with Lei Zhiyong's Digital Economy fund showing strong results, while Wang Dapeng's Health Industry fund underperformed the index and benchmark returns [1][2] - The Digital Economy Mixed A fund managed by Lei Zhiyong has achieved a year-to-date return of 71% as of November 9, significantly outperforming the benchmark by 46 percentage points, and ranking among the top in its category [1] - Over the past year, the Digital Economy fund has delivered nearly 80% returns, exceeding the benchmark by approximately 59 percentage points, and has achieved a remarkable 192% return over the past two years [1] Group 2 - The Health Industry Mixed A fund, managed by Wang Dapeng, has heavily invested in the popular innovative drug sector but has only realized a year-to-date return of 5%, underperforming the benchmark by nearly 11 percentage points [2] - The Health Industry fund has shown negative returns over various time frames, with returns of -2%, -16%, -27%, and -32% over the past year, two years, three years, and five years respectively, all trailing the benchmark returns [2]

Group 1 - Morgan Stanley Fund Management (China) has experienced performance divergence among its fund managers this year, with Lei Zhiyong's Digital Economy fund performing exceptionally well, while Wang Dapeng's Health Industry fund underperformed the index and benchmark returns [1][2] - The Digital Economy Mixed A fund managed by Lei Zhiyong has shown strong performance, achieving a year-to-date return of 71% as of November 9, significantly surpassing the benchmark return by 46 percentage points [1] - Over the past year, the Digital Economy fund has nearly 80% returns, exceeding the benchmark by approximately 59 percentage points, and has achieved a remarkable 192% return over the past two years [1] Group 2 - The Health Industry Mixed A fund, managed by Wang Dapeng, has heavily invested in the popular innovative drug sector but has only achieved a year-to-date return of 5%, underperforming the benchmark by nearly 11 percentage points [2] - Over longer periods, the Health Industry fund has recorded returns of -2%, -16%, -27%, and -32% over the past year, two years, three years, and five years respectively, consistently underperforming the benchmark returns [2]

Group 1 - New Tian Pharmaceutical (002873.SZ) released its Q3 2025 report on October 31, 2025, indicating that as of October 30, 2025, eight institutional investors held a total of 84.1289 million A-shares, accounting for 34.46% of the total share capital [1] - The proportion of shares held by institutional investors increased by 0.41 percentage points compared to the previous quarter [1] - Among public funds, the only fund that increased its holdings this period was the Huatai-PineBridge CSI Traditional Chinese Medicine ETF, with an increase of 0.11% [1] Group 2 - Two new foreign institutions disclosed their holdings this period, including CITIC Securities Asset Management (Hong Kong) Limited - Client Funds and Goldman Sachs [2] - UBS AG was not disclosed in this period compared to the previous quarter [2]

Core Viewpoint - Enhua Pharmaceutical (002262.SZ) reported its semi-annual results for 2025, highlighting significant institutional investment and changes in public fund holdings [1][2]. Institutional Holdings - As of July 29, 2025, 22 institutional investors disclosed holdings in Enhua Pharmaceutical, totaling 374 million shares, which represents 36.83% of the company's total equity [1]. - The top ten institutional investors collectively hold 36.56% of the shares, with a slight increase of 0.09 percentage points compared to the previous quarter [1]. Public Fund Holdings - Three public funds reduced their holdings compared to the previous quarter, with a total decrease of 0.42% [2]. - Twelve new public funds disclosed holdings in Enhua Pharmaceutical, including notable names such as Southern CSI 500 ETF and Dachen Active Growth Mixed A [2]. - Fifteen public funds that previously held shares did not disclose their holdings this quarter, including several healthcare-focused funds [2]. Social Security Fund - One new social security fund, the National Social Security Fund 406 Combination, disclosed its holdings in Enhua Pharmaceutical during this period [2]. Insurance Capital - One insurance company, China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 005L-CT001, increased its holdings by 0.2% compared to the previous period [2]. Foreign Investment - One foreign institution, Hong Kong Central Clearing Limited, did not disclose its holdings this quarter, indicating a potential shift in foreign investment interest [3].

Group 1 - The core viewpoint of the news is that as of March 27, 2025, institutional investors hold a significant portion of Tiger Medical's A-shares, totaling 1.76 billion shares, which accounts for 20.31% of the company's total equity [1] - The top ten institutional investors collectively hold 14.86% of Tiger Medical's shares, with a decrease of 1.43 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, while five funds decreased their holdings, with a total reduction rate of 0.19% [2] - A total of 16 new public funds were disclosed this period, including notable funds such as E Fund CSI 300 Medical ETF and others [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.30% compared to the previous quarter [2]